ASCO Annual Meeting
ASCO Annual Meeting
Perspective from Theodore S. Hong, MD
June 04, 2016
1 min read

Preoperative chemoradiotherapy extends survival in esophagogastric junction adenocarcinoma

Perspective from Theodore S. Hong, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO — Preoperative chemoradiotherapy conferred better survival outcomes than chemotherapy alone among patients with locally advanced esophagogastric junction adenocarcinoma, according to results of the phase 3 POET trial presented at the ASCO Annual Meeting.

“Results with chemotherapy alone are not sufficient. We should be able to improve [on them], and chemoradiation is one of the ways we can do that,” Michael Stahl, MD, director of the department of medical oncology at Kliniken Essen-Mitte in Germany, told HemOnc Today.

Phase 3 trial results published in 2009 showed the addition of preoperative radiotherapy to chemotherapy for patients with locally advanced esophagogastric junction adenocarcinoma increased 3-year survival from 28% to 48%; however, this result did not reach statistical significance.

The POET study included 119 patients with locally advanced disease who were randomly assigned to preoperative chemotherapy (n = 59) or chemoradiotherapy (n = 60). Rates of R0 resection were comparable between treatment groups (68% vs. 72%).

Median follow-up was 10.5 years.

Results revealed a trend toward improved 5-year survival in the chemoradiotherapy group (39.5% vs. 24.4%; HR = 0.65; 95% CI, 0.42-1.01).

Researchers also reported a significant improvement in local PFS after complete resection (HR = 0.42; 95% CI, 0.19-0.93) and improved DFS after complete resection (HR = 0.61; 95% CI, 0.36-1.01) among patients assigned chemoradiotherapy.

“The biggest implication is that we improved local control. By that, we improve long-term survival, and this is really long-term data,” Stahl said.

Results showed significant survival differences by treatment assignment among patients with Siewert type I or type II cancers; however, patients with type II cancer appeared to derive more benefit (HR for type I = 0.71; HR for type II = 0.6).

Stahl and colleagues intend to conduct a confirmatory trial in hopes of establishing preoperative chemoradiotherapy as a standard treatment.

“Another important step would be if we can predict which patients may [benefit most] from immunotherapy,” Stahl added. “It would be very nice to use immunotherapy in the adjuvant setting instead of chemotherapy.” – by Kristie L. Kahl

Reference: Stahl M, et al. Abstract 4031. Presented at: ASCO Annual Meeting; June 3-7, 2016; Chicago.

Disclosures: Stahl reports honoraria from Celgene, Merck Serono, Roche Pharma AG and Sanofi; consultant roles with Baxalta and Merck Sharp & Dohme; and travel, accommodations or expenses from Amgen.